Next Article in Journal
Application of Massively Parallel Sequencing in the Clinical Diagnostic Testing of Inherited Cardiac Conditions
Previous Article in Journal / Special Issue
In Vitro Efficient Expansion of Tumor Cells Deriving from Different Types of Human Tumor Samples
Med. Sci. 2014, 2(2), 82-97; doi:10.3390/medsci2020082

NKT Cell Responses to B Cell Lymphoma

, 1
, 1
, 1
, 1
, 1
, 1
, 2
 and 1,*
Received: 4 October 2013 / Revised: 8 March 2014 / Accepted: 25 March 2014 / Published: 14 April 2014
(This article belongs to the Special Issue Recent Advances in Cellular Immunotherapy)
View Full-Text   |   Download PDF [685 KB, uploaded 14 April 2014]   |   Browse Figures
Abstract: Natural killer T (NKT) cells are a unique subset of CD1d-restricted T lymphocytes that express characteristics of both T cells and natural killer cells. NKT cells mediate tumor immune-surveillance; however, NKT cells are numerically reduced and functionally impaired in lymphoma patients. Many hematologic malignancies express CD1d molecules and co-stimulatory proteins needed to induce anti-tumor immunity by NKT cells, yet most tumors are poorly immunogenic. In this study, we sought to investigate NKT cell responses to B cell lymphoma. In the presence of exogenous antigen, both mouse and human NKT cell lines produce cytokines following stimulation by B cell lymphoma lines. NKT cell populations were examined ex vivo in mouse models of spontaneous B cell lymphoma, and it was found that during early stages, NKT cell responses were enhanced in lymphoma-bearing animals compared to disease-free animals. In contrast, in lymphoma-bearing animals with splenomegaly and lymphadenopathy, NKT cells were functionally impaired. In a mouse model of blastoid variant mantle cell lymphoma, treatment of tumor-bearing mice with a potent NKT cell agonist, α-galactosylceramide (α-GalCer), resulted in a significant decrease in disease pathology. Ex vivo studies demonstrated that NKT cells from α-GalCer treated mice produced IFN-γ following α-GalCer restimulation, unlike NKT cells from vehicle-control treated mice. These data demonstrate an important role for NKT cells in the immune response to an aggressive hematologic malignancy like mantle cell lymphoma.
Keywords: NKT cells; CD1d; mouse models of lymphoma; mantle cell lymphoma; α-galactosylceramide NKT cells; CD1d; mouse models of lymphoma; mantle cell lymphoma; α-galactosylceramide
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Li, J.; Sun, W.; Subrahmanyam, P.B.; Page, C.; Younger, K.M.; Tiper, I.V.; Frieman, M.; Kimball, A.S.; Webb, T.J. NKT Cell Responses to B Cell Lymphoma. Med. Sci. 2014, 2, 82-97.

AMA Style

Li J, Sun W, Subrahmanyam PB, Page C, Younger KM, Tiper IV, Frieman M, Kimball AS, Webb TJ. NKT Cell Responses to B Cell Lymphoma. Medical Sciences. 2014; 2(2):82-97.

Chicago/Turabian Style

Li, Junxin; Sun, Wenji; Subrahmanyam, Priyanka B.; Page, Carly; Younger, Kenisha M.; Tiper, Irina V.; Frieman, Matthew; Kimball, Amy S.; Webb, Tonya J. 2014. "NKT Cell Responses to B Cell Lymphoma." Med. Sci. 2, no. 2: 82-97.

Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert